Sangamo Therapeutics (SGMO) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Sangamo Therapeutics (SGMO) over the last 14 years, with Q4 2024 value amounting to $5.1 million.
- Sangamo Therapeutics' Accumulated Depreciation & Amortization fell 6617.88% to $5.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.1 million, marking a year-over-year decrease of 6617.88%. This contributed to the annual value of $5.1 million for FY2024, which is 6617.88% down from last year.
- Per Sangamo Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $5.1 million for Q4 2024, which was down 6617.88% from $15.1 million recorded in Q4 2023.
- Sangamo Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $15.1 million during Q4 2023, with a 5-year trough of $5.1 million in Q4 2024.
- For the 5-year period, Sangamo Therapeutics' Accumulated Depreciation & Amortization averaged around $9.5 million, with its median value being $9.4 million (2021).
- In the last 5 years, Sangamo Therapeutics' Accumulated Depreciation & Amortization soared by 6559.65% in 2021 and then tumbled by 6617.88% in 2024.
- Sangamo Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $5.7 million in 2020, then soared by 65.6% to $9.4 million in 2021, then grew by 28.28% to $12.1 million in 2022, then grew by 24.71% to $15.1 million in 2023, then crashed by 66.18% to $5.1 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $5.1 million for Q4 2024, versus $15.1 million for Q4 2023 and $12.1 million for Q4 2022.